# A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

> **NCT04272775** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 14 (actual)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04272775
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06-05
- **Primary completion:** 2019-02-15
- **Final completion:** 2019-02-15
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Business Decision; No Safety Or Efficacy Concerns
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272775, "A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04272775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*